{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pulmonary-embolism/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"c60f44ed-a5f4-566e-8718-a289b4d4e969","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 4830534b-f617-43d7-be9e-46f574ff14de --><h2>Changes</h2><!-- end field 4830534b-f617-43d7-be9e-46f574ff14de -->","summary":null,"htmlStringContent":"<!-- begin item 141ca878-e8d8-4424-a60e-4b9d9fd89dfc --><!-- begin field b7505e20-1298-459b-9575-3f577f617876 --><p><strong>October 2020</strong> — minor update. The contraindications of dalteparin have been updated in line with manufacturer's revised SPC.</p><p><strong>March 2020</strong> — minor update. The management section of this topic has been updated in line with the updated NICE guideline <em>Venous thromboembolic diseases: diagnosis, management and thrombophilia testing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">NICE, 2020</a>].</p><p>The prescribing information section has also been updated to include details of oral anticoagulants.</p><p><strong>January 2019 </strong>— reviewed. A literature search was conducted in January 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to clinical recommendations have been made.</p><!-- end field b7505e20-1298-459b-9575-3f577f617876 --><!-- end item 141ca878-e8d8-4424-a60e-4b9d9fd89dfc -->","topic":{"id":"322088c5-226e-5f2b-9fd2-2e2c0678abc1","topicId":"6b233aab-5318-4abb-96fa-1877e917ef2c","topicName":"Pulmonary embolism","slug":"pulmonary-embolism","lastRevised":"Last revised in October 2020","chapters":[{"id":"7d60ce89-0a3c-5336-a5d4-755eb5bfb2cd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"99df9a07-7867-5283-b7c8-4589c8f6e029","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b4da2d8a-f835-512f-b218-660b7fc61806","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c60f44ed-a5f4-566e-8718-a289b4d4e969","slug":"changes","fullItemName":"Changes"},{"id":"42a750f4-f134-55a8-a654-9c23ac2a3bfd","slug":"update","fullItemName":"Update"}]},{"id":"b8001d19-4cf2-5db4-b8b5-f082fbff4fbd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"52656989-9cf4-597c-8118-0fadcb887b21","slug":"goals","fullItemName":"Goals"},{"id":"cdd140ec-bd30-59e9-9777-c921159ea664","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c32413cc-9382-5aaa-b03b-95ed29a1b360","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c1a308a6-aa46-578f-98f1-ed7872474fb4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1629cec2-329a-5273-a313-15a0783d5b22","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d4860e1f-9b8b-5f49-bdb5-fb068af327ab","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9e6802a1-b9c3-5fa9-b632-ef9712c1724b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"588bb6e5-794e-52df-9953-d91254204285","slug":"definition","fullItemName":"Definition"},{"id":"e2fbb90b-8419-52d9-bfd2-a9eab621be3b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ad38abd5-7668-59b3-828a-9edd427dbdd5","slug":"pathophysiology","fullItemName":"Pathophysiology"},{"id":"9b45f610-d957-50a3-9e85-019832acd145","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"8e279dc8-2394-5073-8866-952291c0eee6","slug":"complications","fullItemName":"Complications"},{"id":"8be5980d-145d-5d9c-b255-f057579ce868","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"c07c0850-0c27-58a8-96a8-96051968c076","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1db70c8e-a80c-587a-8e5e-5adf28878587","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"a71fc8ea-c1d7-5be5-a888-41b834fdca93","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"f18a5246-939d-51ce-adb5-f6538871345a","fullItemName":"Management","slug":"management","subChapters":[{"id":"42f102a2-ceab-531f-880e-4075895d9c12","slug":"suspected-pulmonary-embolism","fullItemName":"Scenario: Suspected pulmonary embolism"},{"id":"cd66b55b-908e-56dc-811f-db55be20b710","slug":"confirmed-pulmonary-embolism","fullItemName":"Scenario: Confirmed pulmonary embolism"}]},{"id":"6ae8a494-48a2-5d60-b0f8-39dd5e02489b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8b812684-b06c-50e2-86d7-f012b792c674","slug":"parenteral-anticoagulants","fullItemName":"Parenteral anticoagulants"},{"id":"f367e7b5-6b1b-5f42-9d57-a8edab35855f","slug":"oral-anticoagulants","fullItemName":"Oral anticoagulants"}]},{"id":"c1bef62c-2c5a-5588-af53-1a0b4b26d3e3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3941fd8f-10fb-53d4-8dc1-3835ad3ca3e3","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"26fc4bf9-2995-5109-9f1e-3ba9ad3dd2dd","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f1b2f1f8-81e2-5a3c-b454-2f63f66f6235","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"83fd7f66-6953-54a6-b55f-8d2858a82e97","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"bd9e363f-a674-594d-8bb9-8779d385e06a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"20c76427-9b00-5da0-bd68-6486385780f2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"96a22dd0-587f-5051-8263-acea49ba216b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b4da2d8a-f835-512f-b218-660b7fc61806","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"0031a140-5500-55b5-ae7f-2317f36837c0","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 36733f2a-9c49-48c1-bcb7-d2ef875b77fa --><h3>Previous changes</h3><!-- end field 36733f2a-9c49-48c1-bcb7-d2ef875b77fa -->","summary":null,"htmlStringContent":"<!-- begin item 4b5fb4e6-1c97-4ff6-a677-8b28d58e5270 --><!-- begin field d4a90173-069d-4fc7-88a0-ea544b5ea41a --><p><strong>January 2015</strong> — minor update. Update to the text to correct a minor typographical error. The text regarding the duration of anticoagulant therapy has also been updated to improve clarity.</p><p><strong>February 2014 </strong>— minor update. Update to the text to state that if pulmonary embolism (PE) is suspected in a woman who has given birth within the past 6 weeks, she should be admitted immediately.</p><p><strong>June 2013 </strong>— reviewed. A literature search was conducted in May 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The guideline has been updated to include recommendations on the diagnosis and management of PE made in the National Institute of Health and Clinical Excellence (NICE) guideline <em>Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing.</em></p><p><strong>August 2012 </strong>— minor update. Minor typographical error corrected.</p><p><strong>July 2011 </strong>— minor update. All references to the British Committee for Standards in Haematology (BCSH) guideline on oral anticoagulation with warfarin have been updated to reflect the latest guideline. Issued in September 2011</p><p><strong>November 2010 to February 2011 </strong>— this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field d4a90173-069d-4fc7-88a0-ea544b5ea41a --><!-- end item 4b5fb4e6-1c97-4ff6-a677-8b28d58e5270 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}